Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Cancer immunology research

Volumn 2, Issue 2, 2014, Pages 127-132

  Yuan, Jianda ^a   Zhou, Jun ^a   Dong, Zhiwan ^a   Tandon, Sapna ^a   Kuk, Deborah ^a   Panageas, Katherine S ^a   Wong, Philip ^a   Wu, Xinqi ^a   Naidoo, Jarushka ^a   Page, David B ^a   Wolchok, Jedd D ^a   Hodi, F Stephen ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; TUMOR MARKER; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84996525854     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0163     Document Type: Article

References (0)